Drawing for BRILENCE

USPTO serial 86228360

BRILENCE

Reviewed by CopyMark Law Group

Status 601
Filing date
Status date
Registration date
—
Examiner
—
Law office
NEW APPLICATION PROCESSING

What this means

This page summarizes the public USPTO record for this serial number, including owners, goods and services, and prosecution history.

Need help with BRILENCE?

If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.

Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.

Owner

Attorney of record

The USPTO lists this attorney as the applicant's representative for correspondence on this application.

Richard Friedman

RICHARD FRIEDMAN PFIZER INC.235 E 42ND STNEW YORK, NY 10017-5703UNITED STATES

Goods and services

ClassDescriptionStatusFirst use
005Pharmaceutical preparations for the treatment of cardiovascular, central nervous system, endocrine, gastrointestinal, hematologic, immunological, infectious, inflammatory, menopausal, metabolic, musculoskeletal, neurological, oncological, ophthalmological, psychiatric, respiratory, urogenital, urological and viral diseases and disorders; pharmaceutical preparations for the treatment of erectile dysfunction, sexual dysfunction and pain; pharmaceutical preparations, namely, antifungal preparations, dermatological preparations, smoking cessation preparations; vaccines for human useACTIVE—

Related trademarks

CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.

Prosecution history

DateCodeEventWhat it means
Apr 28, 2014MAB1ABANDONMENT NOTICE MAILED - EXPRESS ABANDONMENT—
Apr 28, 2014ABN1ABANDONMENT - EXPRESS MAILED—
Apr 25, 2014EXARTEAS EXPRESS ABANDONMENT RECEIVED—
Apr 4, 2014NWOSNEW APPLICATION OFFICE SUPPLIED DATA ENTERED—
Mar 25, 2014NWAPNEW APPLICATION ENTERED—

Frequently asked questions

Related guidance